If drugmakers have their way, the federal government likely ends up spending $100 billion of taxpayer funds to bail out rural hospitals.

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

Katherine Denney, Alissa Fleming, Gregory Fliszar Ph.D. In the fall of 2024, several pharmaceutical companies reacted to HRSA's decision to prevent them from implementing a rebate model for their ...

FAH rebuts Senate hearing claims, clarifying taxpaying hospitals do not benefit from the 340B drug pricing program discounts.

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...

Inaccurate information, pushbacks and undue limitations imposed by pharmaceutical manufacturers pose a threat to the 340B ...

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program ...